News on Bristol-Myers Squibb Company

Bristol diabetes pill tied to certain cancers

2011-06-27T09:00:20Z

SAN DIEGO (Reuters) - A new type of diabetes pill being developed by Bristol-Myers Squibb and AstraZeneca was effective in a two-year study but more bladder and breast ca...

Bristol, Astra report diabetes pill cancer rates

2011-06-25T12:00:07Z

SAN DIEGO (Reuters) - A new type of diabetes pill being developed by Bristol-Myers Squibb and AstraZeneca was effective in a two-year study, but the companies said more b...

Bristol-Myers gets drug approvals, awaits more

2010-10-22T19:30:39Z

Drugmaker Bristol-Myers expected to focus on new drug approvals, more on horizon in 3Q report

Bristol-Myers Squibb Co., the maker of popular blood thinners Plavix and Coumadin, is likely to spend some time ...

52-Week Phase 3 Study Found Investigational Drug Dapagliflozin Plus Metformin Similar to Glipizide Plus Metformin in Improving Glycosylated Hemoglobin (HbA1c) in Adults with Type 2 Diabetes Mellitus

2010-09-24T06:19:26Z

...

24-Week Phase 3 Study Found Investigational Drug Dapagliflozin Improved Glycosylated Hemoglobin (HbA1c) When Added to Glimepiride in Adults with Type 2 Diabetes Mellitus

2010-09-21T13:59:46Z

...

Earnings Preview: Bristol-Myers to discuss R&D

2010-07-21T08:16:41Z

Bristol-Myers expected to focus on drug research progress, approval prospects in 2Q report

Drugmaker Bristol-Myers Squibb Co. is expected to focus on a raft of recent positive research data and plans to seek approval for several drugs when it reports its second-quarter results before the stock market opens Thursday.

WHAT TO WATCH FOR: Analysts anticipate detailed updates ...

Bristol-Myers sees big jumps in 1Q sales, profit

2010-04-29T14:45:28Z

Bristol-Myers sees big jumps in 1Q sales, profit, but lowers forecast on health overhaul costs

Drugmaker Bristol-Myers Squibb Co. on Thursday reported double-digit jumps in first-quarter sales and profit, beating Wall Street expectations, but it lowered its 2010 profit forecast by a nickel due to the impact of the health car...

U.S. Food And Drug Administration Accepts New Drug Application For Once-Daily Fixed Dose Combination Of Onglyza (Saxagliptin) And Extended Release Metformin For The Treatment Of Type 2 Diabetes Mellitus In Adults

2010-10-25T11:27:18Z

...

metformin

2010-10-26T23:30:01Z

...

Bristol-Myers gets EU approval for diabetes drug

2010-04-16T09:58:58Z

Bristol-Myers, partner AstraZeneca get EU approval for diabetes drug Onglyza, rival for Merck

Drugmaker Bristol-Myers Squibb Co. said Monday that its new diabetes drug, Onglyza, has been approved for sale in the European Union's 27 countries.

That ...

Study Finds That Onglyza (saxagliptin) When Added To Metformin Was Non-Inferior To JANUVIA (SITAGLIPTIN) When Added To Metformin In Reducing Hemoglobin (HbA1c) In Adults With Type 2 Diabetes Mellitus

2010-10-24T09:16:52Z

...

FDA approves new diabetes drug Onglyza

2010-04-16T11:03:35Z

FDA clears potential blockbuster diabetes drug from drugmakers Bristol-Myers and AstraZeneca

Federal health regulators on Friday approved a potential blockbuster diabetes drug from Bristol-Myers Squibb Co. and partner Astrazeneca PLC.

The Bristol-Myers Squibb appears free from heart-related side effects that have plagued similar treatments, federal health officials said Monday.

Despite low rates of heart attacks and related problems in testing, the Food and Drug Administration will still ask an ...

Onglyza (saxagliptin) With Metformin as Initial Combination Therapy Significantly Lowered A1C and Demonstrated Significant Improvements Across Key Measures of Glucose Control in Treatment Naive People With Type 2 Diabetes

2010-10-23T16:00:07Z

...

Onglyza (saxagliptin) Demonstrated Significant Improvements Across Key Measures of Glucose Control When Added to a Sulfonylurea or Thiazolidinedione in People With Inadequately Controlled Type 2 Diabetes

2010-10-23T16:00:03Z

...

Bristol-Myers Squibb and AstraZeneca Submit New Drug Application in the United States and Marketing Authorization Application in Europe for Onglyza (saxagliptin) for the Treatment of Type 2 Diabetes

2010-10-23T09:21:22Z

...

Onglyza (saxagliptin) Demonstrated Significant Reductions in Key Measures of Glucose Control in Treatment Naive People with Type 2 Diabetes

2010-10-23T09:21:06Z

...

Earns Bristol Myers

2010-07-22T06:30:31Z

FILE - In this file photograph taken July 27, 2006, Excedrin pain medication from Bristol-Myers Squibb is shown New York. Drugmaker Bristol-Myers Squibb Co. said Thursday, July 22, 2010, its second-quarter sales are up a bit but profit is down nearly 6 percent, due to the sale of its interest in a nutrition busine...

Bristol Myers CEO

2010-03-27T02:57:24Z

In this photo released by Bristol-Myers Squibb Co., newly named CEO Lamberto Andreotti is shown. The drugmaker on Tuesday, March 2, 2010 said Andreotti will serve as CEO effective May 4, when current chairman and CEO James M. Cornelius will retire. (AP Photo/Bristol-Myers Squibb, <...